RxDoctor Payments Data

James Hall, MD

Family Medicine · Kansas City, MONPI 1295735504

Payments from drug & device makers

$7,040in general payments, 2019–2025

Across 436 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$745
  • Abbott$696
  • AbbVie$564
  • Novo Nordisk$551
  • Pfizer$460
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,97899%
  • Education$120%
  • Other$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,040 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$166,541
Medicare patients
322
Services billed
5,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$249,357
JardianceEmpagliflozin114$158,742
OzempicSemaglutide129$142,541
Tresiba Flextouch U-200Insulin Degludec50$86,507
FarxigaDapagliflozin Propanediol50$68,088
XareltoRivaroxaban37$55,695
MounjaroTirzepatide44$47,810
AbrysvoRsv Vacc, Pref A And Pref B/Pf130$40,528
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$23,597
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$20,189
Tresiba Flextouch U-100Insulin Degludec36$18,106
ShingrixVaricella-Zoster Ge/As01b/Pf70$15,293
OxycontinOxycodone Hcl26$14,795
EntrestoSacubitril/Valsartan11$12,091
SymbicortBudesonide/Formoterol Fumarate17$10,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$460$289,885333 claims
Boehringer IngelheimJardiance$242$158,742114 claims
Novo NordiskOzempic$551$142,541129 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,091$98,83690 claims
Johnson & JohnsonXarelto$118$55,69537 claims
Lilly USA, LLCMounjaro$745$47,81044 claims
GSKShingrix$61$15,29370 claims
NovartisEntresto$84$12,09111 claims
Astellas Pharma US IncMyrbetriq$257$5,52712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →